346 related articles for article (PubMed ID: 17037948)
21. The treatment of polycystic ovary syndrome.
Ajossa S; Guerriero S; Paoletti AM; Orrù M; Melis GB
Minerva Ginecol; 2004 Feb; 56(1):15-26. PubMed ID: 14973407
[TBL] [Abstract][Full Text] [Related]
22. Polycystic ovary syndrome.
Kahn JA; Gordon CM
Adolesc Med; 1999 Jun; 10(2):321-36. PubMed ID: 10370713
[TBL] [Abstract][Full Text] [Related]
23. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth.
Harwood K; Vuguin P; DiMartino-Nardi J
Horm Res; 2007; 68(5):209-17. PubMed ID: 17426408
[TBL] [Abstract][Full Text] [Related]
24. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome.
Yang PK; Hsu CY; Chen MJ; Lai MY; Li ZR; Chen CH; Chen SU; Ho HN
J Clin Endocrinol Metab; 2018 Mar; 103(3):890-899. PubMed ID: 29325133
[TBL] [Abstract][Full Text] [Related]
26. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.
Sam S; Ehrmann DA
Diabetologia; 2017 Sep; 60(9):1656-1661. PubMed ID: 28770330
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of polycystic ovarian syndrome in adolescents.
Nicandri KF; Hoeger K
Curr Opin Endocrinol Diabetes Obes; 2012 Dec; 19(6):497-504. PubMed ID: 23076041
[TBL] [Abstract][Full Text] [Related]
28. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Ibáñez L; López-Bermejo A; Díaz M; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1262-7. PubMed ID: 21632811
[TBL] [Abstract][Full Text] [Related]
29. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
30. Optimal management of polycystic ovary syndrome in adolescence.
Hecht Baldauff N; Arslanian S
Arch Dis Child; 2015 Nov; 100(11):1076-83. PubMed ID: 26101431
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and management of polycystic ovary syndrome: a practical guide.
Stankiewicz M; Norman R
Drugs; 2006; 66(7):903-12. PubMed ID: 16740005
[TBL] [Abstract][Full Text] [Related]
32. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
33. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women.
Ibáñez L; de Zegher F
Hum Reprod Update; 2006; 12(3):243-52. PubMed ID: 16407452
[TBL] [Abstract][Full Text] [Related]
34. Metformin therapy in women with polycystic ovary syndrome.
Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
[TBL] [Abstract][Full Text] [Related]
35. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Oner G; Muderris II
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):127-31. PubMed ID: 21831508
[TBL] [Abstract][Full Text] [Related]
36. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.
Ibáñez L; Ferrer A; Ong K; Amin R; Dunger D; de Zegher F
J Pediatr; 2004 Jan; 144(1):23-9. PubMed ID: 14722514
[TBL] [Abstract][Full Text] [Related]
37. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
38. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
39. Polycystic ovary syndrome in adolescents: pathophysiology and treatment implications.
Pelusi C; Pasquali R
Treat Endocrinol; 2003; 2(4):215-30. PubMed ID: 15966558
[TBL] [Abstract][Full Text] [Related]
40. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Svendsen PF; Nilas L; Nørgaard K; Madsbad S
Ugeskr Laeger; 2005 Aug; 167(34):3147-51. PubMed ID: 16117910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
